Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TransMedics Group, Inc.
Report date February 01, 2023 · Filed February 03, 2023
Section 16 reporting ended · disclosed 2023-02-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,120 |
Ending reported balance
After 2023-02-01 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2023-02-01 · Exercise / conversion · Acquired 1,363 · Balance 15,483 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Row 2 · 2023-02-01 · Exercise / conversion · Acquired 47 · Balance 15,530 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Row 3 · 2023-02-01 · Sale · Disposed 582 · Balance 14,948 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.23 to $62.22, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 4 · 2023-02-01 · Sale · Disposed 379 · Balance 14,569 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.23 to $63.02, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 5 · 2023-02-01 · Sale · Disposed 96 · Balance 14,473 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $63.43 to $64.41, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 6 · 2023-02-01 · Sale · Disposed 139 · Balance 14,334 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F5: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $64.45 to $65.42, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Row 7 · 2023-02-01 · Sale · Disposed 214 · Balance 14,120 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F6: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $65.45 to $65.96, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.14 · Expires 2030-02-27 | Direct | 4,887 |
Reported balance
After 2023-02-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-02-01 · Exercise / conversion · Disposed 1,363 · Balance 4,887 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F7: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.46 · Expires 2031-02-24 | Direct | 13,543 |
Reported balance
After 2023-02-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-02-01 · Exercise / conversion · Disposed 47 · Balance 13,543 F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F8: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.23 to $62.22, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.23 to $63.02, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $63.43 to $64.41, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $64.45 to $65.42, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $65.45 to $65.96, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020.
F8: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,900 | $15.13 | $28,747.00 |
DisclosureSEC source: 0000899243-20-006952 · doc4.xml · nonDerivative · entry 2 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $14.77 to $15.76, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,000 | $0.39 | $780.00 |
DisclosureSEC source: 0000899243-20-006952 · doc4.xml · nonDerivative · entry 1 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 27, 2020 Filed Mar 6, 2020 23:14 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000899243-20-007519 · doc4.xml · derivative · entry 1 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:43 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-20-003282 · doc4.xml · derivative · entry 3 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,894 Underlying: Common Stock · 2,000 shares Expires 2021-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:43 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,000 | $17.71 | $35,420.00 |
DisclosureSEC source: 0000899243-20-003282 · doc4.xml · nonDerivative · entry 2 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $17.54 to $17.91, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:43 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,000 | $0.39 | $780.00 |
DisclosureSEC source: 0000899243-20-003282 · doc4.xml · nonDerivative · entry 1 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-20-001632 · doc4.xml · derivative · entry 2 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 2,000 shares Expires 2023-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,000 | $0.28 | $560.00 |
DisclosureSEC source: 0000899243-20-001632 · doc4.xml · nonDerivative · entry 1 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:55 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0000899243-20-000554 · doc4.xml · derivative · entry 3 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,894 Underlying: Common Stock · 2,000 shares Expires 2021-09-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:55 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 2,000 | $18.95 | $37,900.00 |
DisclosureSEC source: 0000899243-20-000554 · doc4.xml · nonDerivative · entry 2 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $18.80 to $19.12, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:55 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,000 | $0.39 | $780.00 |
DisclosureSEC source: 0000899243-20-000554 · doc4.xml · nonDerivative · entry 1 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:39 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,200 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0000899243-19-027524 · doc4.xml · derivative · entry 2 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 1,200 shares Expires 2023-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 21:39 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,200 | $0.28 | $336.00 |
DisclosureSEC source: 0000899243-19-027524 · doc4.xml · nonDerivative · entry 1 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 24,437 | Not disclosed Strike: $2.21 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 10 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,437 Underlying: Common Stock · 24,437 shares Expires 2027-06-22 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F3 · derivative.exercise_date: The option vests as a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, June 22, 2017. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 85,530 | Not disclosed Strike: $0.63 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 9 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,437 shares Expires 2027-06-22 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F3 · derivative.exercise_date: The option vests as a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, June 22, 2017. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 28,146 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 8 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,146 Underlying: Common Stock · 28,146 shares Expires 2023-05-29 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 98,514 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 7 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,146 shares Expires 2023-05-29 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 6 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-03-27 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 35,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 5 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-03-27 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 14,894 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 4 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,894 Underlying: Common Stock · 14,894 shares Expires 2021-09-27 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 52,130 | Not disclosed Strike: $0.11 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 3 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,894 shares Expires 2021-09-27 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 262 | Not disclosed Strike: $57.75 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 2 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires 2020-12-16 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 06, 2019 Filed May 6, 2019 22:48 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | OtherStock Option (Right to Buy) · Derivative | 920 | Not disclosed Strike: $16.50 | Not disclosed |
DisclosureSEC source: 0000899243-19-012304 · doc4.xml · derivative · entry 1 Carey John F · CIK 0001774272 · VP of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262 shares Expires 2020-12-16 F1 · derivative.exercise_price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · kind: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · shares: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F1 · price: The Stock Options reported herein as being disposed of are options to purchase common stock of TransMedics, Inc. Immediately prior to the closing of the Issuer's initial public offering, pursuant to the terms of the Agreement and Plan of Merger and Reorganization by and among the Issuer, TransMedics, Inc. and TMDX, Inc., dated April 15, 2019 (the "Merger Agreement"), each outstanding option to purchase shares of common stock of TransMedics, Inc. was converted into an outstanding option to purchase shares of common stock of the Issuer adjusted on a 3.5-for-one basis, with a corresponding adjustment to the exercise price. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.